Whether mild cognitive impairment (MCI) has a distinct neuropathological profile that reflects an intermediate state between no cognitive impairment and dementia is not clear. Identifying which biological events occur at the earliest stage of progressive disease and which are secondary to the neuropathological process is important for understating pathological pathways and for targeted disease prevention. Many studies have now reported on the neurobiology of this intermediate stage. In this systematic review, we synthesize current evidence on the neuropathological profile of MCI. A total of 162 studies were identified with varied definition of MCI, settings ranging from population to specialist clinics and a wide range of objectives. From these studies, it is clear that MCI is neuropathologically complex and cannot be understood within a single framework. Pathological changes identified include plaque and tangle formation, vascular pathologies, neurochemical deficits, cellular injury, inflammation, oxidative stress, mitochondrial changes, changes in genomic activity, synaptic dysfunction, disturbed protein metabolism and disrupted metabolic homeostasis. Determining which factors primarily drive neurodegeneration and dementia and which are secondary features of disease progression still requires further research. Standardization of the definition of MCI and reporting of pathology would greatly assist in building an integrated picture of the clinical and neuropathological profile of MCI.
Background
The concept of mild cognitive impairment (MCI) defines an intermediate state between no cognitive impairment (NCI) and pathological cognitive ageing with the aim of identifying individuals who are at high risk of dementia. Numerous different definitions of MCI have been proposed with large variations in the type of impairment that needs to be present (for example, amnestic vs non-amnestic) and the level of deficit severity that is required. 1 Despite intense research to characterize the neuropsychological and clinical profile of MCI and its progression to dementia, the actual neuropathological substratum has not yet been elucidated for any definition of MCI. Defined as a transitional state, MCI is a difficult biological phenomenon to investigate, especially in terms of testing claims about whether it represents an at-risk state, or is simply early-stage dementia, which itself has multiple possible substrates. In this review, we describe the published literature on the neuropathological profile of MCI (Supplementary Table 1 ). The methodology for article selection is outlined in Supplementary Appendix 1. The focus is on findings which might establish MCI as a distinct and identifiable state between control and dementia groups. Key issues addressed include: (1) the extent to which Alzheimer's disease (AD) and non-AD pathology associated with clinical dementia are observed in MCI; (2) the molecular changes that have been found and, (3) changes in key processes such as neurotransmitter signaling and cellular responses (including downregulation and oxidation).
Diagnosing MCI
Across articles, there is considerable variability in MCI criteria as shown in Supplementary Table 1 . Although the diagnosis of Mayo Clinic-defined MCI (amnestic MCI (aMCI)) 2 is the most widely applied in clinical and research practice, only 45 articles have mapped this definition. The amnestic subtype has been applied almost exclusively (vs non-amnestic or multi-domain MCI). In 55 articles, MCI is defined using a Clinical Dementia Rating (CDR) score of 0.5. However, there is still disagreement about whether such individuals should be included with AD cases. 3 In the Religious Orders Study, which of all studies has produced the most publications (46 articles), the MCI case definition was: 'a neuropsychological impairment (by clinical rating) with no dementia' for all but 1 publication. Therefore, reproducibility of findings in the associations is affected by differences in MCI case diagnosis across sources, neuropsychological testing batteries used to define cognitive impairment and differences in clinical ratings. This is problematic as participants diagnosed with MCI are not directly comparable across all studies. Furthermore, there may be bias towards specific types of pathology (for example, AD pathology) depending on the MCI definition used. Here, we give an overview of all neuropathological findings relating to an immediate cognitive group between NCI and dementia regardless of definition. Further research is necessary to elucidate whether different MCI criteria are associated with different neuropathological profiles, and this would require detailed information on the operationalization of MCI criteria in specific study populations.
Global diagnostic findings
Neuropathological diagnosis of AD The diagnostic scheme usually used is the NIA-Reagan (National Institute on Aging-Reagan Institute criteria) with MCI brains showing a variable dementia probability rating ranging from low (as typically seen in NCI cases) to high (as typically seen in dementia) as shown in Supplementary Table 1 . Similar variability and a high probability of a neuropathological diagnosis of AD is also found when classification is based on the Consortium to Establish a Registry for AD (CERAD) protocol, with MCI brains diagnosed with possible, probable or definite AD, or the Khachaturian criteria with most MCI brains diagnosed as having Alzheimer-type pathology. However, there is also a large proportion of MCI cases that do not show significant AD neuropathological changes. The schemes used to classify AD pathology were designed to distinguish NCI and AD groups, and this could in part explain their lack of discriminative accuracy in categorizing MCI.
Braak NFT Staging
Mild cognitive impairment cases have variable Braak staging scores ranging from a complete absence of pathology (stage 0) to stages V and VI representing severe dementia. Similar variability is seen in NCI and dementia cases. There is no obvious boundary between control, MCI and AD groups using Braak staging. However, it has been suggested that Braak staging is better at identifying MCI groups in which memory is impaired (that is, aMCI) than groups in which memory is intact (that is, non-amnestic MCI (nMCI)). 4 
AD and non-AD pathology
Neuropathological manifestations of AD In terms of AD neuropathology, MCI generally reflects an intermediate state that shares to a certain degree the histopathological hallmarks of AD in vulnerable cortical regions including memory-related regions, the hippocampus and the visual association cortex. In some studies, these changes are interpreted to represent one of the earliest pathological substrates of this condition with MCI more similar to AD than to control cases. 8, 24, 26, [45] [46] [47] 51 Relative to controls, individuals with MCI have been found to show a significant increase in neuritic plaques (NPs) in the neocortical regions 52 and neurofibrillary tangles (NFTs) in the hippocampus, amygdala and entorhinal cortex (EC). 33, 53 In contrast, in other reports, MCI cases are found to be more similar and often indistinguishable from individuals with NCI. 20, 22, 36, 44, [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] These results raise questions regarding the threshold necessary for the burden to be pathological and the existence of neural tolerance or compensation effects that may be related to the severity and location of the pathology (that is, hippocampus and EC spreading to the neocortex and primary visual system at later, more severe disease stages), the presence of disease comorbidity, brain reserve and donor age. 5, 14, 19, 20, 54, 56, 60, [64] [65] [66] [67] Overall, despite variability in MCI definition, generally there is an increased presence of NFTs and NPs, although not always at the level associated with a neuropathological diagnosis of AD.
Abnormal tau has been found to increase with increasing dementia severity measured using the CDR score. Abnormal phosphorylation and conformational changes (MC-1 and TG-3) are observed in mild (CDR = 1)-to-severe (CDR = 5) dementia stages, with MCI (CDR = 0.5) and control (CDR = 0) cases similar. 68, 69 The antibody MC-1 recognizes a pathological, compact conformation of tau that is associated with increased potential for tau to aggregate into paired helical filaments (PHF). 70, 71 The TG-3 antibody recognizes an altered tau conformation when phosphorylated at Thr231. 72, 73 Both these antibodies recognize changes in tau structure and/or phosphorylation at what are considered to be early stages of disease.
Compared with NFT pathology, the severity of plaque pathology has been found to be less discriminating of cognitive status across the NCI-MCI-early AD continuum. 4, 9, 14, 18, 19, 25, 31, 32, 63, 67, 74, 75 In some 19, 20, 44, 76 reports, the volume of plaques seems to remain stable with disease progression, with significant changes only observed at late disease stages. These results have been taken to suggest that abnormal accumulation of plaques is not critical for the transition from NCI to MCI, 56 being necessary only for transitions to dementia. 20 However, the effect of amyloid deposition on cognitive function is understood to be mediated by plaque subtype (greater burden with neuritic vs diffuse plaques), 20, 76, 77 co-occurring NFT burden, 78 apolipoprotein E (APOE) e4 gene dosage, 18, 41, 42 age 42, 56 and compensatory mechanisms linked to education level. 79 Plaque-disease associations may also be missed because of methodological features. 80 By adopting a stereological rather than a semiquantitative approach to amyloid assessment, a significant relationship between cognitive status (CDR score) and the total volume occupied by amyloid deposits in the subiculum and the EC (CDR and Mini Mental State Examination (MMSE) score) has been found. 44 Furthermore, studies of amyloid load based on amyloid-beta-protein (Ab) levels have found that Ab42 (a cleavage product of the amyloid precursor protein: APP) (and Ab43), and to a lesser extent Ab40 correlate with dysfunction in AD and may mediate pathological changes associated with early disease. 57, 69, 77, 81 However, although age-adjusted group comparisons of insoluble Ab40 and Ab42 levels in the cortex correlate with neuropathological AD status (CERAD and Braak staging), 82 they do not correlate with clinical diagnosis at death (NCI, MCI, early AD). MCI and early AD are only distinguishable from controls in terms of the Ab42/Ab40 ratio (both soluble and insoluble). 57 The importance of this change remains to be elucidated.
Overall, there seems to be no clear relationship between the classic neuropathological markers of AD and progression from NCI to MCI. Indeed, even in non-dementia normal groups, the level of pathology can be significant enough for a neuropathological diagnosis of dementia. 83, 84 Whether the neuropathological features are directly involved in disease pathways or are markers for other processes, some of which may be protective, has not yet been conclusively shown. 85 
Ab oligomers
In MCI and mild/moderate AD (CDR = 1 or CDR = 2), there is a progressive accumulation of Ab monomers, dimers and higher-order oligomers in the frontal cortex compared with NCI cases. 86 Levels of oligomers are found to correlate with severity of cognitive impairment (MMSE and Blessed Information Memory Concentration score) and AD neurodegeneration (Braak staging). Furthermore, oligomers appear to interrupt synaptic function as shown by an association with loss of synaptic markers including synaptic vesicle protein vesicle-associated membrane protein-2 and postsynaptic density-95 (a marker of postsynaptic density). Therefore, accumulation of Ab monomers and oligomers seems to be involved in the initial stages of disease resulting in synaptic dysfunction and impaired cognition.
Vascular-related pathology
Very few MCI cases receive a primary neuropathological diagnosis of vascular dementia. 7, 23, 26 However, evidence of vascular disease 29, 87 and vascular-related pathology has been found including infarcts, [7] [8] [9] 19, 26, 37, 88 cortical micro-infarcts, 19, 25, 36, 89, 90 thalamic and basal ganglia lacunes, 36, 50 periventricular demyelination, 50, 89, 90 deep white matter demyelination, 50, 89 subdural hematoma, 88 hippocampal sclerosis, 7, 19, 23, 26 atherosclerosis, 4 cerebral contusion, 23 metabolic encephalopathy 23 and evidence of morphological alterations in capillaries. 91 In one article, in which the sample of individuals was restricted to cases without significant tangle pathology (Braak stage I-II only), the presence of micro-vascular changes including cortical micro-infarcts, deep white matter demyelination and periventricular demyelination in the hippocampus, frontal, parietal and temporal areas predicted cognitive function defined using the CDR score. 89 Similarly, using the same neuropathology resource, 90 micro-infarcts and periventricular demyelination also predicted CDR scores in individuals with significant tangle pathology (Braak stage III). In contrast, focal cortical and white matter gliosis were not associated with clinical outcome.
Interhemispheric distribution of AD and non-AD pathology
The hemispheric distribution of AD and vascular pathology seems to be associated with severity of cognitive impairment (CDR score). 6 AD pathology including NFT and Ab deposition, is found to populate the brain symmetrically even in NCI cases (CDR = 0), with a left predominance of vascular pathology independent of CDR score. However, interhemispheric differences, namely an increase in AD pathology staging and vascular pathology in the right hemisphere, are found to be associated with an increase in CDR score. These results are based on a single study and need to be replicated.
Argyrophilic grain disease
Argyrophilic grain disease has been found in some cases of MCI, 10, 19, 23, 25 but has not been reported routinely, and so it is difficult to discuss particular patterns.
Cerebral amyloid angiopathy
Cerebral amyloid angiopathy has been observed in some cases of MCI, 16, 25, 64 but has also not been investigated systematically. In one study, cerebral amyloid angiopathy was not found to correlate with CDR score. 52 
LB pathology
In rare cases, Lewy body (LB) pathology is found in individuals with MCI 7, 8, 19, 25, 29, 43, 64, 88 and in some is of sufficient severity for a neuropathological diagnosis of LB dementia 10, 23, 26, 43, 87 or mixed AD and LB dementia. 7, 43 In other cases, no evidence of LB pathology is found. 24, 30, 37 No variable currently exists that distinguishes MCI with and without LB pathology in life. However, using cognitive and psychiatric data, one hospital-based autopsy series distinguished a neuropathologically confirmed AD-risk state defined using criteria for aMCI, from a pre-clinical LB dementia state (MCI-LB). 73 LB pathology was found only in MCI-LB cases and more AD pathology (higher Braak, CERAD and NIA-Reagan scores) was observed in the aMCI group, with the exception of diffuse plaques in which the density was comparable.
Atrophy
Relative to NCI cases, MCI and dementia cases show significant loss of neurons in the EC (primarily layers II and IV). 92, 93 This supports in vivo imaging studies of significant degeneration of the EC even before the onset of dementia, in individuals with MCI and in those with subjective memory complaint but no objective memory deficit. 94, 95 In one study, using postmortem magnetic resonance imaging, reduced hippocampal volume was found to accurately predict neuropathological fulfillment of AD criteria in individuals with and without memory impairment. 96 This supports findings from in vivo neuroimaging studies linking hippocampal atrophy to cognitive impairment and MCI. 97 In contrast, only at advanced disease stages (CDR = 3) is significant neuronal loss observed in the superior temporal sulcus. 31, 32 Dendritic spine loss (Sp-ir) Dendritic spines are protrusions from dendritic shafts that are essential for excitatory synaptic transmission in the central nervous system. Dendritic spine loss measured using the total number of spinophilin immunoreactivity (Sp-ir) puncta in the hippocampal CA1 field has been found to be associated with cognitive function (CDR score), but the association was lost after Braak stage adjustment. 98 This suggests that the cognitive consequences of dendritic spine loss in the CA1 are mediated by global NFT burden. In area 9, the association between CDR scores and Sp-ir puncta numbers remained significant even after Braak adjustment, suggesting that neocortical dendritic spine loss may have an independent impact on cognition. In contrast, degradation of the neuronal cell body, nucleus and nucleolus in the hippocampus has been observed only at advanced disease stages. 99 
Synaptic loss
Significant reduction in the synaptic number in the inferior temporal gyrus and volume of the lamina 3 has been observed in AD and aMCI compared with NCI cases. 100 Synaptic counts in the lamina 3 were also found to correlate with MMSE scores and total synaptic number with word recognition and animal naming, but not APOE genotype, plaque density or Braak stage. 100 An electron microscopy study of synaptic loss in the outer molecular layer neurons of the hippocampal dentate gyrus found significant loss in individuals with early-onset AD compared with the MCI and NCI groups. 101 Although there was a reduction in the MCI relative to the NCI group, the results were not significant. Synapse loss did correlate with cognitive performance including MMSE score. 101 Synaptic loss is found to provide a better indicator for cognitive impairment than b-amyloid plaque burden. 102 For a narrative review of synaptic degeneration in MCI and AD see the study by Arendt. 103 Tauopathy in the cholinergic nucleus basalis (NB) area Alzheimer's disease-related neuronal changes have been found in the cholinergic system including an increase in tauopathy (Alz-50 and AT8 immunoreactivity). Alz-50 recognizes a conformation-dependent, non-contiguous, N-terminal epitope of tau and has a high affinity for tau in PHF. 104 AT8 recognizes an epitope doubly phosphorylated at serine 202 and at threonine 205 with some cross-reaction with doubly phosphorylated tau at either serines 199 and 202 or threonine 205 and serine 208.
105,106 Tauopathy containing NB neurons are present in controls and become significantly more prominent with disease progression including MCI and early AD stages. 39 Such changes also correlate with memory performance and are suggested to contribute to memory impairment observed in the NCI-MCI-AD continuum. 39 Although expression levels of tau isoforms, b-tubulin, microtubule-associated proteins and neurofilament subunits was not different across NCI, MCI and early/mild AD, single gene profiling revealed a significant reduction in the expression ratio of three-repeat tau to four-repeat tau mRNAs in cholinergic basal forebrain (CBF) neurons in MCI and AD that does not occur in NCI. 107 This is considered to be linked to aberrant regulation in normal tau function contributing to NFT formation. Therefore, the NB appears to be an early target for NFT changes of AD.
The locus coeruleus (LC) noradrenergic system
Increasing numbers of NFT are seen in noradrenergic neurons projecting from the locus coeruleus (LC) in MCI and early AD (AT8-positive labeling). 108 Changes in the LC correlate with global cognitive function (MMSE score). Although the role of the LC in disease progression is not clear, there is evidence in the wider literature linking changes in the LC to cognitive impairment. 109 Therefore, LC pathology may mediate the onset of cognitive impairment in the NCI-MCIdementia continuum.
Components of the cell cycle
The mechanisms leading to neuronal death and neurodegeneration with disease progression remain unclear. One mechanism is believed to be linked to regionally specific deregulation of various components of the cell cycle. 110 Aberrant expression of cellcycle proteins and unscheduled cell-cycle events are deleterious to neurons and can result in apoptosis and neurodegeneration. 111 In MCI and AD, a significant increase in neurons immunopositive for factors including proliferating cell nuclear antigen involved in control of DNA replication, and the cyclins, cyclin D and cyclin B, involved in regulation of cyclindependent kinases, has been observed predominately in the hippocampus, basal nucleus and EC. 34 The highest level of reactivity has been found in regions with the highest tangle pathology (that is, phosphorylated tau expression levels). Expressions of cyclindependent kinase-2, cyclin-dependent kinase-5 and cyclin G1 have also been found to be increased in MCI and AD in the hippocampus and inferior parietal lobe (IPL), suggesting re-entry of cells into the cell division cycle in early disease phases. 27 However, these results could be indicative of aberrant signaling involving intracellular kinase cascades at early stages of disease progression. 103, 112 Perturbations in cellcycle proteins, with cyclin-dependent kinase-5 being the best studied, could reflect aberrant signaling systems involved in multiple synaptic processes such as axonal transport, 113 organization of the cytoskeleton, 114 tau phosphorylation, 115 synapse formation and dendritic organization, 116 synaptic vesicle endocytosis, 117 ,118 regulation of gene expression 119 and expression of neurotransmitter receptors at the cell surface 120, 121 rather than aberrant entry into the cell cycle per se.
Factors associated with apoptosis
The caspases (Csp) are a family of cysteine endopeptidases involved in the regulation of inflammation and apoptosis. The executioner Csps, namely Csp-3 and Csp-6, promote apoptosis and both are increased in MCI and AD. 122, 123 Caspase gene expression is also altered with an increase in disease severity. 124 In the EC, the messenger RNA expression of Csp-1 and Csp-7 is elevated in MCI (CDR = 0.5), and coincides with increased poly (ADP-ribose) polymerase cleavage but not apoptotic cell injury. 124 At later disease stages (CDR = 5), a greater elevation is observed in Csp-1, Csp-2L, Csp-3, Csp-5, Csp-6, Csp-7, Csp-8, Csp-9 and terminal deoxynucleotidyl transferase dUTP nick-end labeling-positive cells. However, conflicting evidence suggests that expression of Csp-3, Csp-6 (and Csp-7) is not increased by increased signaling earlier in the Csp pathway and instead apoptosis is aborted, promoting neuronal survival. 125 Cleavage of tau at Asp421 (DTau) by Csps is found to occur early in AD tangle evolution. 126, 127 Caspase cleavage of tau has been shown to enhance filament formation, and Csp activation is considered to be induced by the accumulation of Ab. In AD, Csp-cleaved tau colocalizes with Ab 1-42 and activated Csp-3.
126 Csp-6 is activated in neurons on apoptotic insult and the active Csp-6 and tau cleaved by Cps-6 (TauDCsp-6) is found in NP, neuropil threads and NFTs in the hippocampus in all stages of AD (that is, mild, moderate and severe) independent of disease stage and severity. 122 Such changes have also been found in the hippocampus and EC of individuals with MCI and the oldest-old who do not manifest cognitive impairment, being inversely related to global cognitive scores in the latter group. 122 Csp-6 activation is absent in cognitively normal young individuals (aged 12-40 years), and inhibition of Csp-6 may therefore delay or even prevent disease progression. 122 Caspasecleaved tau is detected early in the progression of AD being observed in MCI brains, but not in NCI. 126 However, only at more advanced disease stages including AD and the transitional state between MCI and AD, does DTau become more insoluble. Therefore, Csp inhibitors could be a potential therapeutic target for AD or for the prevention/delay of MCI progression to dementia.
In MCI and early AD, changes to cellular mechanisms associated with neuronal protection against oxidative and other central nervous system stressors have been observed. The expressions of both the proapoptotic protein Bax (Bcl-2-associated X protein) and the anti-apoptotic protein Bcl-2 (B-cell lymphoma 2) are increased. Bax is increased in the IPL after aminophospholipid (PtdSer) asymmetry in MCI and AD (vs NCI) 123 and in the hippocampus. 128 Erythropoietin is a glycoprotein hormone secreted mainly by the kidney. In the brain, it acts as a cytokine and regulates inflammatory and apoptotic pathways. It acts with Bcl-xL (antiapoptotic member of the Bcl-2 family) to inhibit apoptosis. 129 There is an increased expression of the erythropoietin receptor in MCI and early AD in the hippocampus and temporal cortex (layers I-IV), with the highest level in the MCI group observed in the temporal cortex. 37 Heat-shock proteins (HSPs) promote cell survival in response to environmental stressors, including oxidative stress. 130 The molecular chaperones HSP 27 and HSP 70 are increased in areas affected by AD pathology (hippocampus and IPL, but not cerebellum), whereas induction of other HSPs including HSPs 90, 60 and 32 are low. 131 Such changes may have a neuroprotective effect early in the pathogenesis of AD in the MCI stage, reaching peak density in preclinical stages and then diminishing with disease progression. Maintenance of these responses during disease progression may prevent conversion from MCI to dementia in which oxidative stress is the underlying dysfunction.
Peptidyl-prolyl cis/trans-isomerase (Pin1) Pin1 is a nuclear protein involved in the regulation of mitosis and is a negative regulator of the transforming growth factor beta pathway. Pin1 activity and phosphorylated tau levels are found to be increased in the frontal cortex in MCI and AD. 35 Levels of each are positively correlated with each other in MCI (trend) and AD (robust relationship), suggesting that increased Pin1 response in early disease stages may reflect a compensatory mechanism to counteract increases in AD pathology such as neurodegeneration and neuronal apoptosis. Pin1 function has also been found to be abnormal in MCI and AD due to oxidative modification. 132 Outcomes from this have been hypothesized to include NFT formation, neuronal apoptosis, loss of protector protein transported and downregulation of other key proteins, in addition to oxidized and damaged DNA. 132 Regulation of the cell cycle, its role in the brain and regulation of apoptosis are currently not well understood. The contributions of various components of cell-cycle signaling pathways and their relationships to disease progression require further investigation. As described above, both neurotoxic and neuroprotective factors are upregulated in MCI and AD, suggesting that environmental stressors and cellular responses to stress have an important role early in disease progression. Therefore, maintenance of these neuroprotective responses during disease progression may prevent progression from MCI to dementia. However, this requires testing.
Synaptic protein expression
Synaptic protein expression Specific synaptic proteins have been found to have discordant expression across groups depending on the protein studied and the neocortical region investigated. In MCI, drebrin (DRB: an actin-binding protein involved in dendritic plasticity and cell motility) levels are found to be significantly downregulated in the superior temporal cortex (vs NCI) and upregulated in the superior frontal cortex (SFC) (vs NCI and AD). 133 In contrast, cortical synaptotagmin 133 (a group of transmembrane proteins involved in membrane trafficking) 134 and postsynaptic density-95 (frontal cortex) 135 levels do not differ across the NCI-MCI-AD continuum. In a later study, postsynaptic density-95 level was found to be decreased in the hippocampus in aMCI cases relative to controls. 128 In addition, N-methyl-D-aspartate receptor subunit 2A and the low-density lipoprotein receptor-1 levels both of which are associated with postsynaptic density-95 were also decreased in the MCI hippocampus. Using the MCI case definition of Cognitive Impairment no Dementia in an oldest-old sample, synaptophysin levels in the frontal cortex were found to be increased relative to individuals with dementia (mixed subtype). Oldest-old individuals with dementia showed a decrease relative to the non-dementia group (NCI and Cognitive Impairment no Dementia combined). 135 These results were replicated using the CDR score to classify participants with no difference in synaptophysin expression in the EC in the CDR = 0 and CDR = 0.5 groups. 62 Disparity in synaptic protein expression in early disease stages is believed to be linked to changes in dendritic plasticity within regions most vulnerable to incipient AD pathology. For example, the former response is believed to reflect increased vulnerability of the temporal cortex to synaptic dysfunction, and the latter to a plasticity response to compensate for neuropathological damage.
Using a cDNA microarray, genes related to synaptic function, namely synapsin splice variants I ± III of the a-type isoform, were found to be decreased in MCI (CDR = 0.5) in the EC (but not in the visual cortex) compared with NCI cases. 62 No difference was found between MCI and NCI in variant II of the b-type synapsin isoform. Synapsin is involved in neurotransmitter release with the a-and b-type functionally distinct. Type-a has a role in synaptic plasticity and the kinetics of neurotransmitter release. As the MCI and NCI groups had a similar level of AD pathology (NP and NFTs), the results suggest that decreased expression of the a-type synapsin was not due to neuronal loss, but a selective alteration in protein expression. A later study by the same group used protein array analysis to screen 750 proteins of which in MCI (CDR = 0.5), 50 were found to be altered > 2-fold (typically downregulation) compared with the NCI group (CDR = 0). The differentially regulated proteins were categorized into five functional groups including proteins related to synaptic function and neurotransmitters, cytoskeleton and cell adhesion, the cell cycle, apoptosis and transcription and translation. 136, 137 a-Synuclein levels a-Synuclein is normally a soluble protein, localized primarily at the pre-synaptic region of axons. It may regulate dopamine release, induce fibrillization of tau and protect neurons from various apoptotic stimuli. Insoluble a-synuclein levels have not been found to correlate with neuropathological criteria for AD (CERAD or Braak stage) nor clinical diagnosis. 82 However, decreases in soluble a-synuclein in the frontal cortex have been found to correlate with CERAD diagnosis and global neuropsychological scores, and are also found to be significantly lower in early AD vs NCI and MCI. 28 No difference is observed between the NCI and MCI groups. Therefore, a-synuclein pathology levels may be a reliable marker for detecting synaptic changes at early disease stages, but not MCI.
Metabolic factors

Metabolic changes
Peroxisome proliferator-activated receptor g-coactivator-1alpha is a co-activator of the peroxisome proliferator-activated receptor-g and also interacts with sirtuin 3. These molecules are involved in the regulation of fatty-acid metabolism, reactive oxygen species generation and glucose homeostasis. 138 In the hippocampus, peroxisome proliferator-activated receptor g-coactivator-1alpha immunoreactivity decreases with AD progression (CDR score) and is negatively associated with plaque pathology and Ab (Ab 1À42 and Ab 1À40 ). 139 Decreased peroxisome proliferator-activated receptor g-coactivator-1alpha is believed to promote AD neuropathology by Fox03a-mediated responses. However, such changes are only significant at advance AD stages (CDRX2), with levels in MCI (CDR = 0.5) similar to controls. Promotion of peroxisome proliferator-activated receptor g-coactivator-1alpha expression, thereby maintaining glucose homeostasis, may be a promising therapeutic strategy for late-stage AD, but not MCI.
Oxidative/nitrosative damage Evidence of oxidative stress including damage to protein, lipids, as well as nucleic, mitochondrial and ribosomal acids (that is, nuclear DNA, mitochondrial DNA, mRNA and rRNA) and its by-products (for example, carbonyls) are found in both MCI and AD in multiple brain regions, typically those affected by AD (for example, IPL, hippocampus and frontal cortex, but not the cerebellum) when compared with controls. 30, 33, 38, 123, 131, 132, [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] Supplementary Table 2 gives a detailed description of oxidative/nitrosative changes observed in MCI, and for detailed reviews see the studies by Sultana et al., 155 Mangialasche et al., 156 Butterfield et al., 157 Lovell and Markesbery, 158, 159 Bonda et al., 160 Sultana and Butterfield 161 and Markesbery and Lovell. 162 Such changes are believed to occur in a stepwise manner, with a threshold of pathogenesis associated with major changes in protein synthesis and oxidative metabolism consumption occurring during the MCI stage of disease. 163 In AD and MCI, oxidative damage has been implicated in cellular dysfunction, metabolism dysregulation and alteration to antioxidant defense mechanisms. An increase in reactive oxygen species and reactive nitrogen species generation may be associated with impaired signaling and enzymatic functions, ion fluxes and pH regulation, mitochondrial functions and gene expression, which may have a causal role in the onset of dementia through the contribution of several mechanisms associated with cellular neurodegeneration (for example, upregulation of the enzymes that process APP to generate Ab and contributing to NFT and plaque formation), cell-cycle alteration, neuroplasticity, immune response, apoptosis and neuronal cell death. [163] [164] [165] Oxidative stress may be induced by impaired protein synthesis. For example, with disease progression, ribosome dysfunction occurs, resulting in a decreased capacity for protein synthesis in the ribosome, decreased rRNA and transfer RNA levels, and excessive RNA oxidation in memory-related cortical areas including the superior middle temporal gyri and the IPL. 166, 167 Such changes have been linked to impaired neuronal viability and function and oxidative stress. 142, 168 However, the presence of oxidative damage does not always predict clinical diagnosis or AD severity. 168 This raises the question of the extent to which a protein must be oxidized to impact cognition. 165 Protease activity Proteasomes are cellular organelles present in the nucleus and in the cytoplasm the function of which is the clearance of unneeded or modified proteins, necessary for maintaining the internal cellular milieu. Protease activity has been found to be impaired in the brain of individuals with AD and MCI. 143 Thus, this reduction in enzymatic activity could result in an accumulation of damaged proteins that can form protein aggregates (aggresome) and possibly be linked to the neurodegenerative damage observed in AD and MCI.
Endosomal-lysosomal system dysfunction The Rab family of GTPases is involved in intracellular membrane trafficking and signaling, and has been linked to pathways associated with AD including Ab, NFT formation, APP, b-protein precursor, amyloid-b peptide and apolipoprotein E. Altered expression levels and mutations of Rab GTPases have been associated with AD, and have recently been found to be observed as early as MCI. In MCI and AD, a significant increase in the expression levels of genes that regulate early (GTPase rab5) and late (GTPase rab7) endosomes is observed in CA1 hippocampal pyramidal neurons. 169 Changes in the hippocampal CA1 region are found to be associated with impaired neurotrophin receptor signaling linked to neuronal apoptosis including downregulation of genes encoding TrkB and TrkC in MCI and AD. 169 Increase in the gene expression levels of rab4 and rab24 and decreased expression of rab3 are also observed in the CA1 neurons but, only at late disease stages (AD vs MCI and NCI). 169 Relative to NCI cases, protein expression levels of rab5 and rab7 are also found to be increased in MCI and AD in regions vulnerable to AD pathology including the hippocampus and frontal cortex, but not the cerebellum or striatum. In AD, a significant upregulation is also observed in the basal forebrain. 170 Proteomic analysis of insoluble proteins Using proteomics, B125 proteins have been found to exhibit altered detergent-insoluble levels in the temporal cortex in late-onset AD including Ab and tau and those linked to dendritic spines or synapses, cytoskeletal proteins, mitochondrial enzymes, chaperonins, ubiquitination, oxidative stressresponse enzymes and extracellular matrix proteins. 69 By western blot, levels of Ab, APOE, tubulin, 14-3-3, glyceraldehyde 3-phosphate dehydrogenase, cytochrome c, glial fibrillary acidic protein and myelin basic protein were also found to be increased in prodromal AD (defined as no dementia and a Cognitive Abilities Screening Instrument score < 90) relative to controls. In contrast, tau protein was only found to be elevated at late AD stages, being indistinguishable in control and prodromal groups. Overall, these results have been taken to suggest that the pathological process leading to abnormal proteins is not exclusively linked to AD-related pathology, such as Ab and tau.
Antioxidant enzymes
Individuals with MCI show alterations in the antioxidant system, designed to counteract the potentially hazardous reactions that are initiated by oxidative stress (for example, reactive oxygen species). 152 In the MCI hippocampus, superoxide dismutase activity, glutathione-S-transferase activity and the glutathione (involved in metabolic regulation and essential for cellular detoxification)/oxidized glutathione disulfide ratio is decreased. In contrast, there is a significant increase in the level of superoxide dismutase activity and glucose-6-phosphate dehydrogenase activity compared with agematched controls. Overall, the results suggest that antioxidant imbalance may have a role in dementia progression.
Neurotransmitter systems
Cholinergic system and its markers Selective degeneration of CBF neurons, including a loss of choline acetyltransferase (ChAT) activity within the NB, has been implicated in the development of neurological disorders including AD. Loss of cortical and hippocampal ChAT activity has been found to correlate with AD severity and disease duration [171] [172] [173] (for a review see Schaeffer and Gattaz 174 ). However, such changes have only been found to occur in late disease stages. 171 In NCI, MCI and early/mild AD cases, ChAT activity is found to be stable in the inferior parietal, superior temporal and anterior cingulate cortices, 172 as well as in neurons within the basal forebrain 175, 176 and primary visual cortex. 177 Relative to controls and individuals with mild AD, individuals with MCI have been found to show an elevation in ChAT activity in the hippocampal 15, 172 and neocortical regions. 21 Activation in the SFC is also significantly elevated compared with controls but not significantly different from AD. 172 Upregulation of cortical ChAT activity is believed to be linked to compensatory mechanisms early in the disease process. 15 The mechanism by which this is achieved is suggested to be linked to the altered metabolic status of cholinergic neurons that project to the SFC, rather than an increase in fiber projection. Indeed, a significant loss of ChAT-like immunoreactive (ChAT-ir) fiber and axon varicosity in the SFC has been found in early AD with comparable densities in the NCI and MCI groups. 15 A similar metabolic change is observed in the NB as reflected by an increase in the size of the Golgi apparatus in MCI. 178 Increased NB metabolic activity may reflect a compensatory response to incipient pathology, reflecting the upregulation of cortical ChAT activity. Such metabolic changes may be a marker of disease transition from early to late AD stages. Expression levels of the vesicular acetylcholine transporter protein do not vary significantly across clinical groups. 175 Nicotinic and muscarinic cholinergic receptor binding Although disruption to nAChR (nicotinic acetylcholine receptor) binding has been observed in the midfrontal cortex in patients with AD (vs NCI), nAChR receptor binding is unchanged in MCI (vs NCI). 22 Disruption to nAChR binding is believed to be a secondary outcome after development of AD pathology. Indeed, loss of high-affinity nicotinic agonist binding (epibatidine binding) in the temporal cortex (Brodmann areas 22 and 26) has been found to correlate positively with CDR score, with only small decrements in the groups with none/mild impairment (CDR = 0 or CDR = 0.5). 179 Furthermore, although expression levels of the muscarinic AChRs (mAChRs) subtype mRNAs among NB neurons is unchanged in NCI, MCI and mild/moderate AD cases, increased expression of the a7nAChR subunit mRNA within NB neurons has been found in mild/moderate AD (vs NCI or MCI), 180 but not in the SFC. 61 Increases in a7 may reflect a compensatory neuroprotective response to maintain basal cortical cholinergic activity in the presence of pathological changes associated with AD. The contributions of the various cholinergic receptor subtypes to regulation of cholinergic signal transmission both pre-and post-synaptically, are not well understood; and hence, how changes in the cholinergic receptor subtype may contribute to cognitive impairment and disease progression is not clear.
Galanin
The signaling peptide galanin is closely associated with cholinergic function in the human brain and is co-expressed in a subset of cholinergic neurons within the NB. 181, 182 Galanin hypertrophy within the anterior NB subfield only occurs at late AD stages. 183 It is currently unclear whether galanin contributes to dementia progression by inhibiting cholinergic signaling 182 or is protective by promoting neuronal function and survival. 184 Evidence that noradrenergic neurons co-expressing galanin that project from the LC survive for longer, supports the protective hypothesis. 185 Further investigation is required to clarify the contribution of galanin to disease progression.
Neurotrophins
Although ChAT activity is not found to be significantly altered in MCI, recent observations suggest that regulation of CBF neurons may be abnormal. The high-affinity nerve growth factor (NGF)-specific receptor tyrosine kinase TrkA (and TrkB and TrkC) density has been found to be significantly reduced in MCI and AD (mild and severe) in cholinergic neurons of the NB compared with controls. 176, 186, 187 In contrast, TrkA levels have been found to remain stable in the cortex in MCI with significant declines only in mild/moderate and severe AD cases. 188 Furthermore, NGF levels in CBF cortical target sites including the anterior cingulate, superior frontal, inferior parietal, superior temporal, middle temporal regions and hippocampus also remain stable with disease progression (that is, NCI, MCI, mild and severe AD). 189 There is also a marked reduction in the number of p75 neurotrophin (p75 NRT )-immunopositive neurons in the NB in MCI and mild AD. 75 In contrast, p75
NRT levels are stable in the cortex in NCI, MCI and mild/ moderate/severe AD groups. 188 This change is not due to downregulation of p75 NTR gene expression in CBF neurons, which is found to be stable across clinical groups. 176 Brain-derived neurotrophic factor (both precursor and mature forms), necessary for CBF neuronal survival and function is significantly reduced in the parietal cortex in early AD and MCI relative to controls. 190 Furthermore, although brain NGF-like immunoreactivity in cortical and hippocampal structures remains stable with disease progression, 189 the level of its precursor pro-form of NGF (pro-NGF), is significantly increased in the inferior parietal cortex in MCI and early AD. 191 In addition, the extracellular collagenase matrix metalloproteinase-9 degrades mature NGF. During progression of AD, matrix metalloproteinase-9 (and pro-matrix metalloproteinase-9) is unregulated in the cortex. 192 Matrix metalloproteinase-9 activity also correlates with cognition (Global Cognitive Scores and the MMSE) and Braak stage. These findings indicate an alteration in the NGF cascade early in disease progression, at the MCI stage.
Overall, the results suggest that there are differences in expression changes across different cortical projection sites of cholinergic NB neurons depending on the cholinergic marker and disease severity. Overlap in the neurotrophic molecular pathology in MCI and AD suggests that such changes occur early in the pathogenesis of disease and support MCI as prodromal AD. The findings support a role for altered neurotrophin responsiveness rather than frank neurodegeneration of cholinergic neurons as a possible early biomarker for AD. 193 The biological consequences of such changes are still unclear. Further refinement of the neuropathological changes in the NB system and their functional significance remains outstanding.
Neuropeptides
Both NCI and MCI cases (CDR = 0.5) are not found to differ on cortical levels of somatostatin-like immunoreactivity or corticotptrophin-releasing factor. 173, 194 In contrast, significant differences between dementia and NCI cases are found in cortical levels of corticotptrophin-releasing factor (reduced at mild and advanced stages; CDR = 1-5) and somatostatinlike immunoreactivity (reduced only at advanced disease stages; CDRX4). 194 
Glutamatergic system
Paradoxical alterations in non-cholinergic synaptic integrity have also been observed in MCI relative to control and AD groups. Changes include an upregulation of glutamatergic pre-synaptic boutons in the midfrontal gyrus 195 and increased DRB levels in the frontal cortex. 133 These changes are followed by successive depletion with increased severity of AD (mild to severe). Such changes are believed to reflect a counter response to pre-existing synaptotoxicity to improve transmission probability, thereby allowing maintenance of cognitive capacity early in disease progression. Alternatively, it has been suggested that they may be due to an uncoordinated atypical response in early disease stages. 195 
Other factors
Concanavalin-A-associated brain proteins
Relative to controls, altered levels of protein phosphatase-related protein Sds-22 (Sds22), glial fibrillary acidic protein, dihydropyrimidase-2 and glucoseregulated protein 78 are found in the MCI hippocampus. 196 Levels of the latter two proteins are decreased, and the former increased. The only protein with altered levels in the inferior temporal lobe was b-synuclein, with a decrease in levels relative to controls. 196 These proteins support different functions known to be disrupted in AD including metabolism, cellular trafficking, neurotransmission and signal transduction.
Tissue transglutaminase
Tissue transglutaminase is involved in catalyzing the formation of protein cross-links and has been associated with apoptosis and neurodegeneration. 197 Tissue transglutaminase immunoreactivity and enzymatic activity in the frontal gray matter is reported to be intermediate in individuals with MCI and highest in individuals with AD. However, cross-group differences are not significant. Furthermore, isopeptide, the catalytic product of tissue transglutaminase, although higher in AD (vs NCI and MCI), is not statistically different across clinical groups. 29 Metal homeostasis Zinc (Zn) is an essential co-factor for many proteins including the zinc-finger containing transcription factors and is therefore involved in many cellular processes through regulation of gene expression. Perturbations in Zn homeostasis have been implicated in the pathogenesis of AD and MCI. In both AD and MCI, regional-specific alterations in the Zn transporter protein-1 (ZnT-1) have been observed. 198 In AD relative to controls, reduced brain ZnT-1 expression is found in the amygdala, hippocampal/ parahippocampal gyrus and IPL, and an increase in expression in the superior middle temporal gyri. 198 In both early-and late-stage AD, an increase in ZnT-4 and ZnT-6 is seen in the hippocampal/parahippocampal gyrus. 24 In aMCI when compared with agematched controls, an increase in ZnT-1 levels is observed in the superior middle temporal gyri (similar to the results from early-AD cases) but, in contrast to the results from AD groups, MCI cases show depletion of ZnT-1 in the hippocampal/parahippocampal gyrus. Levels of ZnT-4 and ZnT-6 although increased in MCI do not differ from controls in any regions tested including the hippocampal and hippocampal/parahippocampal gyrus, superior middle temporal gyri and the cerebellum. 24 Alterations to Zn-transported proteins seem to occur early in the transition from MCI to AD in regions most vulnerable to AD pathology. The exact mechanism(s) by which Zn changes affect cognition remains unknown, but given its role as a cofactor, multiple processes may be affected and such changes are believed to contribute to plaque formation (that is, Ab aggregation) and neuronal degeneration. 198 Cortical sortilin levels Sortilin is a sorting receptor involved in protein transport from the endoplasmic reticulum and the Golgi apparatus to other cellular compartments. It is also involved in protein clearance and acts as a receptor for neurotensin. In the superior frontal and temporal cortical areas, sortilin levels have been found to remain stable with disease progression (NCI-MCI-AD). Furthermore, in MCI, levels do not differ by domain subtype (aMCI vs nMCI). However, frontal cortical levels do positively correlate with age and temporal levels positively correlate with Braak staging and NIA-Reagan diagnosis. 199 
CN/NFAT
The multicomponent nuclear factor of activated T cell (NFAT) transcription complex has roles in the regulation of gene transcription and is dephosphorylated by the Ca 2 þ -and calmodulin-dependent phosphatase calcineurin (CN). CN has roles in multiple systems including regulation of cyclic AMP-dependent kinases and dephosphorylation of histones. Isoform and brain regional-specific changes of NFAT have been observed as a function of disease state. 200 In hippocampal nuclear fractions, NFAT1 is increased in MCI relative to controls, with NFAT3 showing a slight decrease. In AD, NFAT1 is slightly decreased and NFAT3 markedly reduced relative to controls. These patterns were not observed in cerebellar tissue. The pattern coincides with the nuclear accumulation of CN, suggesting translocation of NFATs from cytosol to the nucleus with disease progression. Furthermore, accumulation of CN (subunit Aa) and NFAT3 correlate with soluble Ab 1À42 levels in the hippocampus. Therefore, such changes in CN/NFAT signaling may be driven by the Ab 1À42 elevations and contribute to the progression of dementia. Alternatively, both changes in Ab 1À42 and CN/NFAT may be responding to other changes as yet unknown.
Sirtuin 1
Sirtuin 1 (SIRT1) is an NAD-dependent protein deacetylase involved in many cellular processes, from regulating apoptosis 201 to regulation of cellular metabolism and inflammatory and stress responses. 202, 203 SIRT1 directly affects processing of the amyloid precursor protein by upregulating a-secretase ADAM10, leading to reduced production of Ab. 202, 204 When comparing NCI, MCI and AD groups levels of SIRT1 are found to be similar in the parietal cortex. 205 Only at advanced AD symptomatic stages and in the presence of a high degree of Ab and tau accumulation is a significant SIRT1 decrease observed. 205 As such, a decrease in SIRT1 occurs at late disease stages and therefore does not appear to be a target for MCI. However, as a protective factor, SIRT1 is the focus of investigations that may lead to therapeutic interventions that delay dementia progression. 202 
Inflammation
Neuroinflammatory processes characterized by the upregulation of complement proteins involved in innate immunity including C1q, C3c, C3d, C4c, C4d, iC3b (early-stage complement activation), C9 (latestage complement activation) are found to be associated with Ab plaques containing the fibrillar Ab peptide. 206 Complement activation in plaques in the inferior temporal gyrus 63 and neocortical areas 207 is found to increase with disease progression, with the MCI and NCI groups generally showing a similar level of activation. In addition, the membrane attack protein, Cb5-9, is rarely seen before the onset of clinical dementia. 207 Therefore, upregulation of complement proteins does not appear to be involved in the cognitive changes seen in early disease stages. 63, 207 The expression of cyclooxygenase-2, a marker of inflammation, increases with dementia progression (CDR score) in hippocampal neurons in areas CA1, CA2 and CA3. 208 However, the expression in MCI cases (CDR = 0.5) does not differ from that in controls across each hippocampal subregion. Rather, only at later disease stages (CDRX1) is expression significantly increased in areas CA2 and CA3. In area CA1, significant elevation in expression is only observed at severe, late stages of disease (CDR = 5). Cyclooxygenase-2 maybe a predictor of neurodegeneration, with changes in expression correlating with moderate and severe NP and NFT pathology in the CA3 subdivision, and to a lesser extent in area CA2. However, not all inflammatory markers are found to be associated with disease progression. Interleukin-6 and transforming growth factor-b1 are found to be elevated in dementia, but only at the late severe stages of disease (CDR = 5). 209 Interleukin-6 was also increased in cases with high levels of NFT pathology. Microglia activation measured using human leukocyte antigen-DR immunohistochemistry increases with AD progression (CDR score, NP and to a lesser extent NFTs) in both the gray and white matter of the EC, with significant changes at moderate (CDR = 2) and severe stages (CDR = 5). 210 In the hippocampal area CA1, a significant change is observed earlier (CDR = 1), and in the dentate gyrus, it is observed as early as MCI (CDR = 0.5). Independent segments of the inflammatory cascade seem to be activated at different stages of disease. Therefore, anti-inflammatory drugs need to be adapted depending on the stage of disease at which they are being targeted.
Heme degradation
Biliverdin reductase A (BVR-A) is part of the catabolic pathway of hemoglobin which, together with heme oxygenase, leads to the formation of bilirubin and carbon monoxide. The action of heme oxygenase produce a ferrous iron, CO and biliverdin which through the action of the BVR-A is converted into bilurubin. Total BVR-A protein levels are significantly increased and activity (phosphorylation on Ser/Thr/ Tyr residues) is significantly decreased in the hippocampus (but not in the cerebellum) in aMCI and AD compared with controls. 211 BVR-A in the hippocampus (but not in the cerebellum) is also found to undergo post-translational oxidative and nitrosative modifications in AD and aMCI groups, including a significant reduction in protein carbonyl-derivatives of BVR-A in aMCI and AD compared with controls. 212 In both the AD and MCI groups in the hippocampus, there is also a significant increase in 4-hydroxynonenals (4-NE) levels relative to controls. In contrast, BVR-bound 4-hydroxynonenals is not found to be modified across NCI-MCI-AD groups in either the hippocampus or cerebellum. 212 The increase in BVR-A expression in AD and MCI could potentially represent an adaptive mechanism to compensate for the reduced enzymatic efficiency as demonstrated by a significant reduction in the phosphorylation of serine, threonine and tyrosine residues and marked reduction in BVR-A reductase activity. These adaptive mechanisms could be induced by reducing insulin signaling, which is associated with reduced phosphorylation of BVR-A. A compensatory increase in heme oxygenase activity can lead to an increased CO production with concommitant increases in blood flow and nutrient supply. Additionally, an increased concentration of biliverdin may stimulate the expression of BVR-A.
Autophagy
Autophagy, the pathway involved in intracellular degradation of long-lived proteins and organelles, has been implicated in the pathogenesis of AD. Dysfunction in the autophagy system is believed to result in the accumulation of misfolded proteins. 213 In MCI, Beclin 1, a protein that has a central role in autophagy and apoptosis, has been found to be decreased in the affected brain regions suggesting that reduced autophagy promotes AD progression. 214 Therefore, enhancing autophagy by increasing Beclin 1 levels may be beneficial to preventing disease progression.
Alterations in membrane lipid composition
Modifications of the normal lipid and protein content of cellular membranes and the myelin sheath may be linked to the pathogenesis of neurodegenerative disorders. A decrease in ethanolamine plasmalogen (PE) may be involved in AD-specific related neurodegeneration as PE contributes to the glycerophospholipid fraction of myelin and plasma membrane. In NCI, PE content was higher in the white than in the gray matter and they also differed in the type of fatty-acid species incorporated in the PE molecule. 215 No difference was found in the distribution of PE between brain areas. The PE content of the white matter in subjects with MCI (CDR = 0.5) decreased in all the measured regions compared with controls, but an increase in CDR score was not associated with further decline in PE levels. On the contrary, the decrease in the gray matter was proportional to CDR scores and PE content varied across brain regions (except in the cerebellum). In addition, across the NCI-MCI-AD continuum, a significant decrease in myelin basic protein immunoreactivity has been found. 216 Myelin basic protein has roles in the formation and maintenance of the axonal myelin membrane and may also be involved in signaling pathways in neural cells. However, although the level of change in the AD group is significantly different from that in the NCI group, change in the MCI group is not distinguishable from either the AD or NCI groups.
Sulfatides and ceramides
Sulfatides are a class of sulfated galactosylceramides (STs) involved in several physiological functions (cell growth, signaling, neuronal plasticity). STs are synthesized primarily in the oligodendrocytes and incorporated into the myelin sheath of axons and therefore present in both the white and the gray matter. Altered levels of STs and ceramides (derived from the degradation of STs and involved in the modulation of inflammatory responses) in human brain tissues may be invoked in the pathogenesis of neurodegenerative disorders. A decrease in STs in both the white and the gray matter was observed in very mild dementia (CDR = 1), but an increase in CDR score was not associated with further changes in ST levels. 217 The NCI and MCI groups did not differ. The content of ceramides increased in the white matter in subjects with mild dementia (CDR = 1), but surprisingly, a progressively decline was observed with an increase in neuropathology (CDR = 2 and CDR = 3). Ceramide content in the gray matter was not associated with CDR scores.
Gene expression abnormalities
Using microarray analysis, differences in the pattern of aberrantly expressed genes, namely downregulation, as a function of dementia severity (CDR score) has been found. 218 In MCI, the greatest transcriptional abnormalities are observed in the temporal and parietal cortices, with the hippocampus and frontal cortex less affected until later disease stages. As disease progresses (CDRX2), more brain regions become involved (that is, visual cortex and posterior cingulated gyrus) and an increase in the number of upregulated genes is observed. The regional pattern of alterations in gene expression is also found to change only slightly depending on the method used to classify disease severity (that is, CDR score, Braak stage or NP density). This study suggests that gene therapies for AD targeted at early disease stages would need to be adjusted for later disease stages in terms of areas of vulnerability. However, the specific targets were not outlined.
Neuropathology and cognitive profile
Mild cognitive impairment is a heterogeneous condition and each neuropsychological subtype (that is, aMCI vs nMCI) may possibly reflect a different neuropathological profile. Indeed, a single case study 219 of a patient with executive MCI identified a pattern of pathology reflecting an early stage of the frontal variant of AD that is distinct to the profile typically observed in aMCI including pathology in the temporal, EC, parietal and occipital cortices. Jicha et al. 73 distinguish a pre-LB dementia state from a pre-AD state based on cognitive and non-cognitive (psychiatric symptoms) symptoms again with varying neuropathological profiles. Riley et al. 4 reported that the presence of memory impairment (vs non-memory impairment) is associated with more severe AD pathology (NFTs indexed by Braak staging) and increased severity of atherosclerosis than in individuals with intact memory and impaired non-memory performance. Furthermore, poor early-life linguistic ability (measured using idea density) is found to be associated with an increased likelihood of a neuropathological diagnosis of AD, but not vascular-related pathologies including infarcts (lacunar or large brain infarcts) and moderate-to-severe atherosclerosis. 220, 221 When subtypes of MCI have been assessed, nMCI cases less often have a pathological diagnosis of AD or mixed AD-vascular pathologies compared with aMCI cases. Only macroscopic infarcts without AD are more frequently observed in nMCI cases. In terms of pathological diagnosis, results have been found to be similar for both aMCI and nMCI subtypes: pure AD was the most frequent diagnosis and > 75% of individuals in both groups were found to have an intermediate likelihood of AD (NIA-Reagan criteria). Critique of studies and approach (7) tissue handling procedures (differences in postmortem interval) (8) neuropathological methods (stereological vs semiquantitative approaches vs ultra-structural studies; antibody staining differences) and regions/mechanisms of study interest, as well as (9) the interval between diagnosis and death and therefore the possibility of MCI case transitions to dementia at the time of death. Agreement in MCI criteria for defining groups and clearer reporting of sample demographics, operationalization of MCI criteria and handling methods would assist the integration of findings. To date, there is not enough consistency in any of these parameters to be able to combine studies for analysis.
Summary
The opportunity to examine the brains of individuals who have been in the intermediate pre-clinical stage of cognitive decline when they die is relatively challenging. The pathological profile of MCI is heterogeneous and many factors seem to be on a continuum rather than neuropathologically specific as anticipated. 222 Most associations are confined to single studies and a few individuals. This may in part be due to the difficulty in operationalization of MCI at the end of life. Furthermore, there is the lack of a clear boundary between cognitive stages as dementia onset is gradual by definition. A major obstacle in identifying the pathological substrate of any disease is distinguishing changes that have a causative role from those that are secondary to disease or are compensatory. Pathological changes identified in MCI cases may suggest that this state is already dementia. The concept of pre-MCI has instead been proposed as the earliest marker of cognitive impairment. 26, 223 However, the majority of pre-MCI cases have been found to have neuropathologically confirmed AD, similar to findings reported in aMCI and revised-MCI groups. 26 
Outstanding questions and conclusions
This review highlights the complexity inherent in the study of neuropathological changes associated with MCI. The results suggest that many different processes underlie cognitive decline and dementia and that MCI cannot be understood within a single framework. Multiple neuronal processes, including synaptic processes, neuronal homeostasis, intracellular signaling cascades and gene expression, have been investigated and suggested to be affected at very early stages of cognitive decline as shown in Figure 1 . To date there is no definitive profile that characterizes the state of MCI. This will require representative brain tissue banks that use standardized MCI criteria, neuropathological protocols including staining and scoring techniques. This will enhance our understanding of the pathological process involved in dementia, the risk factors for dementia progression and whether MCI can be distinguished from early AD. With population ageing, this is important, especially to inform the development of effective early intervention strategies.
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